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The extraordinary genetic diversity and immune evasion of human immunodeficiency virus 
(HIV) pose significant challenges for vaccine development. AIDS vaccine design requires 
a scientifically driven, rational approach that encompasses the latest advances in viral 
molecular genetics, structural biology, and immunology.More than 60 million people have 
been infected with HIV-1 since its 
discovery over 20 years ago, and 
of these, more than 20 million have 
died. Natural immunity to the virus is 
virtually nonexistent, and a vaccine 
to prevent AIDS remains elusive. As 
the toll of human suffering, social 
disruption, and economic instability 
grows, the resolution of this intrac-
table problem remains one of the 
greatest opportunities to use sci-
entific research to promote human 
health on a global scale. Although 
antiretroviral therapy has extended 
the lives of HIV-infected individu-
als, these expensive drugs are not 
readily available in the develop-
ing world, nor can they eradicate 
infection. In contrast, a successful 
AIDS vaccine offers the promise of 
preventing symptomatic disease, 
if not infection entirely. Arguably, 
more has been learned about the 
molecular biology, immunology, and 
pathogenesis of HIV-1 infection than 
those of any other virus in history. 
So why has a vaccine not emerged, and what scientific questions must 
be resolved to develop an effective 
vaccine against HIV?
The proof of concept for any suc-
cessful vaccine lies in its ability to 
protect against infection with the 
pathogen. In the absence of natural 
immunity to the AIDS virus, scientific 
understanding of the disease drives 
an approach to vaccine development 
known as “rational vaccine design.” 
From our knowledge of viral patho-
genesis, hypotheses are developed 
about the characteristics of a suc-
cessful vaccine, and these are ulti-
mately tested through efficacy trials 
in humans. A key to success is to first 
identify the most relevant mecha-
nisms of immune protection. For HIV, 
two biological features of the virus 
have posed the biggest impediments 
to developing a vaccine: its extraor-
dinary genetic diversity (reviewed in 
Korber et al., 2001), and the evasive 
properties of its envelope protein. Pre-
cisely how HIV-1 evades the humoral 
(antibody) immune response is still 
being deciphered, but, in the esti-Cell 124, Febmated 70 years since HIV-1 crossed 
the species barrier from chimpanzees 
to humans (Korber et al., 2000), its 
contemporary diversity dwarfs that 
of many other entire virus families. 
Immune mechanisms that confer 
some degree of protection include 
the T cell response that controls dis-
ease progression (established by 
nonhuman primate studies), analysis 
of infected humans that are long-
term nonprogressors, and selection 
of escape mutations in the epitopes 
of CD8+ T cells. Although genetic 
resistance to HIV infection has been 
described in individuals with a mutant 
CCR5 chemokine receptor, an essen-
tial coreceptor for entry, this protec-
tion results from inefficient viral repli-
cation and is not mediated by immune 
recognition of the virus. The humoral 
immune response has the ability to 
neutralize some viruses, but muta-
tions in the variable regions of the 
envelope protein continually generate 
viral escape variants in most infected 
subjects. Critical to the development 
of a successful AIDS vaccine will be Table 1. Candidate AIDS Vaccines in Advanced Clinical Trials
Vector Insert Immune Profile Manufacturer or Sponsor
Canary poxvirus ± protein Env (E), Gag/Pol (B), Env (B, E) Cellular ± humoral Aventis/Vaxgen
rAd Gag (B), Pol (B), Nef (B) Cellular Merck
DNA/rAd Gag (B), Pol (B), Nef (B), Env (A, B, C) Cellular ± humoral VRC, NIAID, NIH
AAV Gag (C), PR (C), RT (C) Cellular IAVI
Lipopeptides Gag (B), Pol (B), Nef (B) Cellular ANRS
Description of AIDS vaccines under evaluation in phase II or phase III clinical trials. Shown are the HIV gene products (insert) delivered 
in the vaccine (vector), the expected immune responses (immune profile), and the manufacturer or sponsor. Letters in parentheses indi-
cate the clade of origin for each viral gene product. rAd, replication-defective adenovirus; AAV, adeno-associated virus; Env, envelope 
protein; Gag, group-specific antigen; Nef, negative regulatory factor; Pol, polymerase; PR, protease; RT, reverse transcriptase.ruary 24, 2006 ©2006 Elsevier Inc. 677
Figure 1. Structures and Targets of Neutralizing Antibodies that Block HIV 
Entry into Host Cells
Shown is the trimeric HIV-1 spike protein composed of three gp41 subunits (gray), three gp120 
core units (light and dark red), N-linked carbohydrate (purple), and sites vulnerable to potential 
antibody-mediated neutralization (green). Broadly neutralizing antibodies against HIV interfere 
with the CD4 binding site of gp120 (antibody b12), the carbohydrate determinants of the spike 
(antibody 2G12), or conserved domains in the membrane-proximal region of gp120, which me-
diate fusion of the viral envelope with the target-cell membrane (antibodies 2F5 and 4E10) (re-
viewed in Burton et al., 2005). In the orientation shown, the left two gp120 molecules overlap 
(dark red), and a protomeric core (bright red) is clearly seen in the rightmost gp120. Note that 
HIV-1 gp120 is shown here in its CD4 bound conformation; the structure of unliganded SIV gp120 
(Chen et al., 2005) demonstrates that considerable conformational reorganization occurs upon 
binding of gp120 to the CD4 receptor of host T cells. Inset figures show structures of broadly 
neutralizing antibodies (light blue) and, where known, their HIV-1 epitopes (green).our ability to elicit immunoglobulins 
that inactivate diverse viral strains—
that is, broadly neutralizing anti-
bodies—and generate strong CD4+ 
and CD8+ T cell immune responses. 
Recent vaccine candidates advancing 
in clinical trials have focused primar-
ily on inducing cellular immunity using 
gene-based vectors, such as DNA, 
replication-defective adenovirus, or 
poxvirus (Table 1). These vaccines 
primarily intend to stimulate either 
CD4+ and CD8+ T cell responses or 
CD8+ T cells alone. Success in elic-
iting broadly neutralizing antibodies 
has been limited to date, although it 
is anticipated that such candidate 
vaccines will be tested in the future, 
either alone or in combination with T 
cell-based vaccines.
Generating Broadly Neutralizing 
Antibodies
Structural and antigenic character-
ization of the HIV-1 envelope reveals 678 Cell 124, February 24, 2006 ©2006 Eunprecedented mechanisms for 
evading the host antibody response. 
The viral spike is composed of  three 
gp120-gp41 glycoproteins. It binds 
to CD4 and a coreceptor on the host 
T cell surface and promotes fusion 
of HIV-1 and host-cell membranes, 
enabling virus entry (see Figure 1). 
Much of its exposed surface is cloaked 
by N-linked glycan, which is produced 
by the host cellular machinery and is 
largely unrecognized by the immune 
system. This glycan surface provides 
an evolutionarily efficient means of 
escape from neutralizing antibodies; 
a small number of mutations can give 
rise to significant changes in glycan 
structures that confer resistance to 
neutralization. The virus uses other 
evasive mechanisms: immunodomi-
nant regions that are occluded in 
the native oligomeric spike protein of 
the virus are exposed in viral debris 
or in inactive forms of the spike pro-
tein. These immunodominant regions lsevier Inc.generate HIV-specific antibodies, 
which do not bind to the functional 
spike. Conformational masking also 
contributes to the resistance of the 
virus to neutralizing antibodies. The 
coreceptor binding site on gp120 of 
HIV is highly conserved, and neu-
tralizing antibodies develop readily 
against it. However, on functional viral 
spikes, the potentially susceptible site 
of coreceptor binding is formed only 
after attachment of gp120 to CD4 
on the host-cell surface, preventing 
access of neutralizing antibodies to 
an otherwise highly conserved bind-
ing site. When these mechanisms of 
humoral evasion are coupled to the 
extraordinary natural diversity of the 
virus, the task of generating high titers 
of broadly reactive, neutralizing anti-
body in vaccine subjects is daunting.
Fortuitously, the technologies that 
reveal the challenges of eliciting 
such antibodies provide insights into 
potential vulnerabilities. Monoclonal 
antibody and phage display analyses 
have identified a few broadly neutral-
izing antibodies. For example, anti-
bodies such as 2F5, 4E10, 2G12, and 
b12 neutralize a significant percent-
age of circulating HIV-1 primary iso-
lates (Burton et al., 2005), and their 
molecular structures and targets are 
now well characterized (Figure 1). 
Why are these antibodies effective?
One answer may be that they rec-
ognize functionally constrained, con-
served, and exposed structures—that 
is, the viral spike must find a recep-
tor and then fuse viral and target-cell 
membranes. These twin functions of 
“finding” and “fusing” provide con-
straints on the viral spike, which may 
be recognized by such antibodies as 
b12 (CD4 binding) or 2F5 and 4E10 
(membrane fusion). The functional 
rationale for conservation of the 
2G12 carbohydrate epitope, which 
is largely limited to clade B viruses, 
is less clear and may relate to pre-
serving advantageous interactions 
with the innate immune system (for 
example, interaction with the carbo-
hydrate binding receptor DC-SIGN) 
or constraints on carbohydrate den-
sity related to glycan shielding.
The information derived from struc-
tural analysis of broadly neutralizing 
monoclonal antibodies informs vac-
cine design. Precise characterization 
of the structures recognized by these 
antibodies is the first step in creat-
ing polypeptides or small molecules 
that mimic such epitopes. To this 
end, significant effort has been made 
to gain an atomic-level understand-
ing of susceptible epitopes and their 
interaction with neutralizing antibod-
ies. The guiding hypothesis is that the 
proper presentation of a functionally 
conserved, susceptible epitope will 
lead to the elicitation of antibodies 
that recognize the target epitope and 
neutralize the virus. To overcome the 
conformational flexibility of the HIV 
envelope protein, modern tools of 
protein design can be used to cre-
ate mutations that fix gp120 into the 
form recognized by the CD4 receptor 
or by broadly neutralizing antibodies. 
To help focus the immune response, 
one can remove immunodominant 
regions, thus paring the envelope to 
critically conserved regions of the 
core or outer domain, or one can mask 
immunodominant regions with carbo-
hydrate to make them immunologi-
cally silent. Another strategy regarding 
epitope presentation involves the cre-
ation of epitope-transplant scaffolds. 
In this scaffolding strategy, the target 
epitope is transplanted into a foreign 
scaffold that replicates both the con-
formation and the surface accessibil-
ity of the epitope as recognized by a 
broadly neutralizing antibody. These 
approaches apply structural infor-
mation to vaccine design: Although 
attractive, this process remains a 
working model and has yet to achieve 
the goal of solving the neutralizing-
antibody problem.
Whether immunogens created by 
epitope mimicry will allow antibodies 
to be elicited with properties similar to 
the original broadly neutralizing anti-
body will depend on a number of vari-
ables: the uniqueness of the template 
antibody, the degree of structural 
mimicry between epitope mimetic and 
antibody bound epitope, and the abil-
ity of the humoral immune system to 
recreate specific immune responses. 
The tools of conformational stabiliza-
tion, epitope focusing, and scaffold 
transplantation have much to contrib-ute to rational vaccine design. Once 
the appropriate antibody immuno-
gens are generated, it may be equally 
important to ensure that relevant 
antibodies are synthesized not only 
in the systemic circulation but also at 
mucosal sites that serve as portals of 
primary infection.
The Cellular Immune Response
In the past, “traditional” vaccine 
design has tended toward an empiri-
cal approach, which has often been 
at odds with traditional cellular immu-
nology—a discipline that is firmly 
hypothesis driven and centered 
on well-characterized inbred mice. 
Human immunology, particularly in 
the field of infectious disease, has 
often relied on phenomenological 
descriptions of disease with impre-
cise measures of immune responsive-
ness. However, the rational approach 
to vaccine design for HIV has neces-
sitated a revised approach to the 
study of cellular immunity in humans. 
Fortunately, recent technological 
advances have furnished enormous 
analytical power that has facilitated 
an understanding of the mechanisms 
of immune protection to infection.
Studies of HIV pathogenesis indi-
cate that the bulk of CD4+ T cell 
depletion occurs on a massive scale, 
predominantly at intestinal mucosal 
surfaces, within a short time period 
after the onset of infection. These 
findings were made possible through 
the ability to sample multiple lym-
phoid tissues in infected nonhuman 
primates and humans and to per-
form sophisticated measurements 
of numerous immunological parame-
ters. These findings have fundamen-
tal implications regarding the site and 
timing of the delivery of therapeutic 
agents to HIV-exposed individuals 
and also affirm that the abatement of 
HIV replication at mucosal surfaces 
is likely to be integral to the success 
of a prophylactic vaccine.
There is strong evidence from 
human studies that virus-specific T 
cell responses are critical to the con-
trol of viral replication in many chronic 
persistent infections, including those 
caused by cytomegalovirus (CMV), 
Epstein-Barr virus (EBV), and hepati-Cell 124, Febtis viruses B and C. However, for HIV, 
the questions remain whether we 
can (1) define the mechanisms and 
correlates of immunity and (2) trans-
late those principles into the design 
of effective vaccines. Critical to the 
success of a T cell-based vaccine 
are five major features of the HIV-
specific cellular immune response: 
its size, phenotype, function, struc-
ture, and anatomical location.
An effective CD8+ T cell response 
is likely to be required for control of 
HIV replication in the chronic phase 
of the disease. In the case of chimeric 
simian and human immunodeficiency 
viruses (SHIV) and perhaps simian 
immunodeficiency viruses (SIV), vac-
cine-induced T cell responses are 
associated with an improved out-
come. However, the quantitative fre-
quency alone of either CD4+ or CD8+ 
virus-specific T cells seems not to 
correlate with viral load or clinical out-
come, implying that quality rather than 
quantity contributes to an effective 
immune response. Definition of the 
character of such immune responses 
requires a refined and comprehen-
sive approach to immune analysis 
in humans. Indeed, the recent use 
of polychromatic flow cytometry to 
measure multiple phenotypic and 
functional parameters of T cells stim-
ulated with vast libraries of peptides 
that represent the entire HIV proteome 
has revealed valuable immune corre-
lates. Individuals with nonprogressive 
chronic HIV disease possess HIV-
specific T cells whose phenotype and 
elaboration of multiple effector func-
tions more closely resemble those of 
CMV- and EBV-specific T cells, which 
apparently successfully contain their 
respective infections (Pantaleo and 
Koup, 2004). An inherent problem 
with an observational approach, how-
ever, is one of causality, such that the 
phenotype and functional profile of 
virus-specific T cells may be a con-
sequence of virus control rather than 
its cause. Nevertheless, it is highly 
likely that, with the extension of such 
multiparameter immune analysis to 
large-scale vaccine clinical trials, we 
will begin to establish rules that deter-
mine the correlates of effective immu-
nity elicited by vaccination.ruary 24, 2006 ©2006 Elsevier Inc. 679
Figure 2. Rational Vaccine Design
Improving our understanding of vaccine im-
munogenicity and subsequent disease pro-
tection relies on applying knowledge about 
(1) viral genetic diversity (depicted in the den-
drogram), (2) the protein structure of major 
histocompatibility complex I (MHC I) proteins 
of the host and gp120 of HIV-1, and (3) the 
ability of these proteins to generate protective 
immunity. Improved mechanistic understand-
ing of these three areas, as well as of vectors, 
adjuvants, and modes of delivery, will acceler-
ate future vaccine development. The ultimate 
aim of rational vaccine design is to develop 
scientific principles and algorithms that pre-
dict protective immune responses in the host 
based on knowledge of the virus and the host 
immune system. This process is likely to be 
iterative and to provide information about im-
mune epitopes that will guide the selection of 
the vectors and gene products most likely to 
confer immune protection against a specific 
infectious agent.The “structure” of a virus-specific 
T cell response comprises a complex 
set of features including the number of 
epitopes targeted (response breadth) 
and their relative immunodominance, 
the clonal composition of epitope-
specific T cell responses, and the 
mode of interaction between epitope-
specific T cell receptors and their cog-
nate antigens. Importantly, this line of 
investigation relates directly to the 
phenomenon of viral epitope escape 
by sequence variation, perhaps one 
of the greatest obstacles to effective 
control of HIV replication. Evidence 
is accumulating that the preferential 
targeting of particular HIV epitopes by 
the CD8+ T cell response may confer 
better, or sometimes worse, disease 
outcomes. These observations are 
reflected in the well-described associ-
ations of HLA histocompatibility com-
plex variants with disease outcome in 
humans and likely reflect the balance 
between the host immune response 
to a viral epitope, the propensity of 
the epitope to escape the immune 
response, and the biological fitness 
of viruses to contain such sequence 
variation. There is also evidence that 
particular T cell clones may directly 
affect patterns of epitope escape. The 
key is that the accumulation of data 
from many thousands of HIV-infected 
individuals worldwide that identify 
preferentially targeted epitopes, the 
timing and nature of epitope escape, 
epitope-specific T cell clonal usage, 680 Cell 124, February 24, 2006 ©2006 Eand HLA type and disease outcome 
should allow us to predict the nature 
of the T cell response that we need to 
elicit with a vaccine to prevent disease 
(or, in certain cases, the type of T cell 
response that should be avoided in 
particular human populations). Fur-
thermore, the principles established 
could then be applied to the ratio-
nal design of immunogens that elicit 
desired T cell responses and can be 
incorporated in a successful vaccine.
In truth, there is still no direct 
evidence that HIV-specific T cell 
responses prevent or retard HIV-1 dis-
ease progression. Yet what we have 
learned from the phenotypic, func-
tional, and structural analysis of virus-
specific cellular responses to CMV, 
EBV, SIV, HIV, and other viral infec-
tions suggests principles for an effec-
tive vaccine. Such a vaccine against 
HIV should elicit (1) a high frequency 
of polyfunctional T cells, especially 
those with the ability to secrete inter-
leukin-2 and to proliferate; (2) T cells 
whose antigen receptors show high 
functional avidity for viral epitopes; 
(3) T cells that target epitopes where 
viral fitness constraints curb their abil-
ity to mutate; (4) T cells with recogni-
tion properties that are better able 
to detect escape mutations and viral 
quasispecies; and (5) T cells at muco-
sal surfaces, which are the first T cells 
likely to come into contact with HIV-
infected cells. All of these principles 
will guide critical aspects of vaccine lsevier Inc.design, including the route of immuni-
zation, mode of antigen presentation, 
antigen dose and persistence, and 
use of immunomodulatory adjuvants.
The Future: A Global and 
Scientific Perspective
The majority of HIV-infected indi-
viduals do not live in nations with 
immediate access to the advanced 
technologies required for sophisti-
cated immune analyses. Clinical tri-
als therefore require unprecedented 
cooperation between scientists in the 
developed and the developing world. 
This effort will require the cooperation 
of governments internationally, non-
governmental organizations, and the 
private sector and the development of 
clinical and laboratory infrastructure. 
Clinical trials must be performed with 
appropriate ethical review, together 
with the willingness of all partners to 
evaluate vaccine efficacy rigorously 
and with transparency. Thus, we 
must further develop these technolo-
gies in such a way that they may be 
used in the field as part of the large 
clinical trials that will surely point the 
way toward an effective HIV vaccine. 
These goals have been embraced 
in the research community through 
such efforts as the HIV Global Enter-
prise, an international consortium of 
collaborative nongovernmental and 
governmental organizations.
It is important to recognize that 
there are several potential outcomes 
in such trials. One possibility is that 
the vaccine will prevent infection. 
This response, typical of classical 
vaccines, is unlikely to occur with 
first-generation prototypes of AIDS 
vaccines. More likely, the vaccine 
may affect the clinical course of the 
disease, not preventing infection but 
instead reducing the viral load and 
prolonging symptom-free survival. 
Finally, such a vaccine may or may 
not affect person-to-person trans-
mission, a parameter that will require 
independent evaluation and that will 
be essential for halting the spread of 
AIDS. These efforts will benefit from 
the definition of immune correlates 
and the use of molecular genetic 
analyses to accelerate clinical evalu-
ation. Without such innovations, it 
would probably take decades more 
to develop a highly effective vaccine.
In the future, knowledge gained 
from clinical efficacy studies of HIV 
vaccines should accelerate the devel-
opment of improved vaccines. At the same time, such trials will advance 
our understanding of new immuni-
zation vectors not only for AIDS but 
also for emerging infectious diseases. 
Critical for progress will be expanded 
knowledge of protein structure, anti-
genicity and immunogenicity, vector 
development, and the correlates of 
protective immunity. Although devel-
opment of an effective vaccine against 
HIV-1 must overcome enormous bar-
riers, the tripartite task of deciphering 
viral genetic diversity, manipulating 
envelope protein structure and MHC 
I epitope recognition, and inducing 
protective immunity provides a ratio-
nal system with which to tackle the 
problem of the ability of HIV to evade 
neutralizing antibodies and cytotoxic 
T cells (Figure 2). Application of this 
knowledge through bioinformatics, 
systems biology, bench science, and 
clinical trials will lead to improved 
paradigms for vaccine design and will 
facilitate the identification of effective 
preventive vaccines in the future.Cell 124, FebACkNowlEDgmENTS
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